Melanoma's secret to cheating death has finally been revealed
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Pittsburgh scientists led by Jonathan Alder, Ph.D., discovered that TPP1 promoter mutations combined with TERT promoter mutations produce the exceptionally long telomeres that make melanoma cells effectively immortal.
- TERT mutations appear in roughly 75% of melanoma tumors but couldn't alone explain the cancer's unusually long telomeres — TPP1 promoter mutations were the previously missing piece.
- Pattra Chun-on, M.D., an internist pursuing her Ph.D. in Alder's lab, introduced both mutated TERT and TPP1 into cells, and the two proteins together generated the long telomeres characteristic of melanoma tumors.
- Earlier work from Alder's lab had identified frequent TPP1 mutations in cancer mutation databases, and biochemists had shown over a decade earlier that TPP1 boosts telomerase activity in a test tube — but the clinical connection was new.
- The study, published in Science (Vol. 378, Issue 6620), identifies a cancer-specific telomere maintenance system that researchers say could become a promising target for future melanoma therapies.
- The research was supported by NIH grants R35CA209974 and R01HL135062, with co-authors from UC Santa Cruz and Johns Hopkins University.
Why it matters: Roughly 75% of melanoma tumors carry TERT mutations, making the newly implicated TPP1 pathway a broad-population target rather than a niche one. Drug developers now have two identified molecular handles on the cancer's telomere maintenance system instead of one, giving melanoma therapeutics a concrete second entry point grounded in patient tumor genetics.
